about
Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectivesAminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CAminoadamantanes versus other antiviral drugs for chronic hepatitis CNitazoxanide for chronic hepatitis CAminoadamantanes for chronic hepatitis CReview and management of drug interactions with boceprevir and telaprevirHepatitis C virus protease inhibitor-resistance mutations: our experience and reviewAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesAntiviral drugs for viruses other than human immunodeficiency virusHepatitis C Viral Infection in Children: Updated ReviewManagement of HCV-Associated Liver Cirrhosis.Conceptual framework for outcomes research studies of hepatitis C: an analytical reviewManagement of hepatitis c genotype 4 in the liver transplant settingRecent Advances in Antiviral Therapy for Chronic Hepatitis CRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseTreating hepatitis C - what's new?Sofosbuvir treatment and hepatitis C virus infectionAdvances in hepatitis C therapy: What is the current state - what come's next?Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis CHepatitis C genotype 4: The past, present, and futureStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesNK cell function and receptor diversity in the context of HCV infectionChronic Hepatitis C Infection in Children: Current Treatment and New TherapiesHepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and ManagementHepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsThe health benefits of vitamin KHepatitis C: Treatment of difficult to treat patientsPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewChronic hepatitis C: future treatmentNatural history and clinical response: "it's the virus, stupid, or is it the host?"Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis CThyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspectiveMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusOral antiviral therapies for chronic hepatitis C infectionAntiviral treatment of hepatitis C virus infection and factors affecting efficacyHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyEmerging therapies for hepatitis CDrug-drug interactions during antiviral therapy for chronic hepatitis C
P2860
Q21265028-6A37A417-1C1A-446C-B6D9-D2FCE8D2E546Q24193940-8C367CE7-016D-4A82-B07F-141DE75BB8EAQ24194770-3DBE2C42-CEA2-47CE-BF01-A8813BADCBF8Q24194815-E99BD4C6-0CBF-4661-AE15-E16988F223F9Q24197485-EDE015F8-42E6-42E0-B9B0-C56CEF5BF960Q24201226-0E3B8E2B-ADCB-4DF3-A070-3571BBDC51AEQ24628716-3EDEA761-BD7D-45B8-9C3A-AA0F0DF85A1FQ24628717-A7EA31A2-FF42-4A33-BD6D-865B3760DB0CQ24632766-2F111D1B-98F4-454C-B5B2-4B760B8CB2C7Q24635330-9A6B522F-1BBB-4691-ACB1-C67E3BE45E88Q26738856-738A9AD8-35CC-4994-A412-50207D1CCD36Q26740320-654849C3-3D1F-46FE-A82C-D020F7EC0BC1Q26745582-9E1EA369-FC7B-42ED-B5BC-400EC63BE3CBQ26749326-C6EE58EE-1E12-4A9D-9F04-B50B3933B766Q26750476-10F9C308-28EE-4D10-B19E-7154898A22C9Q26752433-B2549A16-35BE-4CCF-95CF-B433F957AB53Q26769646-A42BB47D-0DC2-4E26-869E-A25A3DCBBD6EQ26770024-41202F87-5A1B-4B5B-B3EA-6F4BD1FFC5A2Q26770036-A655A7AD-D82A-42D4-ACBF-16D31DBB0F3BQ26773283-A46C9A44-8B00-4DAC-AC56-2DA9A6458F86Q26775815-5178886E-BF89-4AEC-BB7E-75FAAB5F6F85Q26777086-08CF71AD-B71A-47F0-B474-991E549C9118Q26781537-5287A155-7671-4E2C-9EE2-B45A564B759DQ26781770-12AB91AB-3119-4D6A-9412-EF5B79896D94Q26781984-A3514ABC-A4D8-441B-8EC9-5835B9BD1670Q26782033-F8B0E9B4-92ED-4CC2-926F-A5165E67530CQ26782816-01A72B5C-7C31-40B6-8A11-9497F050BAFAQ26798465-52E76CE0-42CF-4943-A3BC-EE5894B35A72Q26798477-B6E8D64B-AFB8-42A1-B241-B0FE669D816EQ26800050-84345181-4C31-4761-A196-3B2439BCE903Q26824075-AFA67BCE-0663-45DE-BA17-73DDA640F652Q26824094-125E0A68-90E3-4C52-B22F-B80B647CD36BQ26825715-223DF81E-0470-42A4-B7DF-1D0BF7BE1BEAQ26827517-A25897A3-3BA6-49AD-B2A6-F9D43AF18AA8Q26830190-C79DC3A2-4D81-46CB-AEFC-DDA8A3D349EEQ26830426-C855F614-94EE-4133-820C-806823B7D55FQ26851810-2CADE17C-3BDE-4848-A69B-0FC9AD9D8848Q26853500-2F5D8CFA-09D7-47CF-B199-67DD86033CCFQ26853642-96FB0E7B-1F61-45E7-BDED-0C8343DB798EQ26864887-FB51C8CD-8CAA-45E5-A1E7-D67D10BE83F0
P2860
description
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2011
@ast
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 23 June 2011)
@en
wetenschappelijk artikel (gepubliceerd op 2011/06/23)
@nl
наукова стаття, опублікована в червні 2011
@uk
مقالة علمية (نشرت في 23-6-2011)
@ar
name
Telaprevir for retreatment of HCV infection
@ast
Telaprevir for retreatment of HCV infection
@en
type
label
Telaprevir for retreatment of HCV infection
@ast
Telaprevir for retreatment of HCV infection
@en
prefLabel
Telaprevir for retreatment of HCV infection
@ast
Telaprevir for retreatment of HCV infection
@en
P2093
P3181
P356
P1476
Telaprevir for retreatment of HCV infection
@en
P2093
Andreone P
Boogaerts G
De Meyer S
Focaccia R
P304
P3181
P356
10.1056/NEJMOA1013086
P407
P577
2011-06-23T00:00:00Z